Replies to post #1637 on Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Of course the $64,000 question regarding Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) trial is whether it will be effective. Yesterday I kept on thinking what Dr Raj said at a recent CC. That in addition to the preclinical data, they dosed one patient (compassionate use) and the result seemed encouraging, and in addition to the promising result in the 1 pt, they were expecting results for the trial this year. I was hoping he wasn't exaggerating. Well, this PR does quote John Heymach, M.D., Ph.D., Chairman, Professor, and David Bruton Junior Chair in Cancer Research, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center (that's saying a mouthful:))

We have already seen encouraging results in a patient with this mutation who was recently treated with poziotinib on a compassionate basis. We look forward to further results from this trial later this year.”

So what Dr Raj said seems to be truthful and accurate and backed up by the prestigious MD Anderson Cancer Center. That is positive in many ways. So maybe something extra in our Christmas stocking in Dec?